Jack Leslie
About
Jack is a Lecturer in Cancer Immunology at Newcastle University. After finishing his PhD in the immunology of organ fibrosis he completed a joint post-doc between the Newcastle Fibrosis Research Group and the CRUK Beatson Institute where he investigated the role of neutrophils in immunotherapy resistance in liver cancer. Jack started his own research group in the Biosciences Institute at Newcastle University in 2022, where they use high parameter flow cytometry and multiplexed imaging technologies to profile patient tumour samples as well as characterise and investigate mouse models of treatment resistant gastrointestinal cancer.
Education
- PhD – The cell specific contribution of cRel dependent signalling in tissue repair, fibrosis and cancer – Newcastle Univeristy (2014 - 2017)
- MRes – Medical Sciences (Distinction) - Newcastle University (2013 – 2014)
- BSc(Hons) – Biomedical Sciences (First) – Newcastle University (2010 – 2013)
Awards and prizes
- 2017 - Academic Development Scholarship
- 2016 - Young Investigator Award at the first international meeting for tissue regeneration, repair and fibrosis
- 2016 - MRC Doctoral Training Partnership Supplement
- 2014 – Mres Poster prize
Conferences, Talks and Presentations
- UK and Ireland NF-kB workshop (2017)
- BASL young investigators workshop (2017) – Two talks
- The first international meeting for tissue regeneration, repair and fibrosis (2016) – Talk
- Newcastle University Practicalities conference – Invited speaker
- North East Renal Research Mini Symposium (2016) – Long talk
- North East Postgraduate Conference (2016) - Talk
- UK and Ireland NF-kB workshop (2015) – Short talk and poster
- North East Renal Research Mini Symposium (2015) – Long talk
Publications
- A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. Zeybel M, Luli S, Sabater L, Hardy T, Oakley F, Leslie J, Page A, Moran Salvador E, Sharkey V, Tsukamoto H, Chu DC, Singh US, Ponzoni M, Perri P, Di Paolo D, Mendivil EJ, Mann J, Mann DA. Mol Ther. 2017;25(1):218-231. IF 6.938
- A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. Luli S, Di Paolo D, Perri P, Brignole C, Hill SJ, Brown H, Leslie J, Marshall HL, Wright MC, Mann DA, Ponzoni M, Oakley F. J Hepatol. 2016 Jul;65(1):75-83. IF 11.055
- Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease. Fox C, Cocchiaro P, Oakley F, Howarth R, Callaghan K, Leslie J, Luli S, Wood KM, Genovese F, Sheerin NS, Moles A. Sci Rep. 2016 Feb 2;6:20101 IF 5.578
- A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-κB dependent liver regeneration and cancer. Moles A, Butterworth JA, Sanchez A, Hunter JE, Leslie J, Sellier H, Tiniakos D, Cockell SJ, Mann DA, Oakley F* and Perkins ND * (Joint Corresponding authors) Oncogene. 2016 Feb 8. IF 8.459
- c-Rel and its many roles in cancer: an old story with new twists. Hunter JE, Leslie J, Perkins ND. Br J Cancer. 2016 Jan 12;114(1):1-6. IF 5.569
- Ubiquitin C-Terminal Hydrolase 1 (UCHL1); A Novel Functional Marker for Liver Myofibroblasts and a Therapeutic Target in Chronic Liver Disease. Wilson CL, Murphy LB, Leslie J, Kendrick S, French J, Fox CR, Sheerin NS, Fisher A, Robinson JH, Tiniakos DG, Gray DA, Oakley F, Mann DA. J Hepatol 2015, 63(6):1421-8. IF 11.055